Who
James A. Robinson Jr.
Director
Company insider
Files Form 4 as: Director, UroGen Pharma; Director, Eledon Pharmaceuticals; Director, Applied Genetic Technologies; PEO;CEO/Urovant Sciences, Inc., Urovant Sciences; Director, Neos Therapeutics; President & COO,Alkermes, Inc., Alkermes.
In numbers
- Trades disclosed
- 55
- Buys
- 0
- Sells
- 0
- Bought
- $0
- Sold
- $0
- Companies
- 6
- Companies where not an officer
- 4
- First trade
- 4 Apr 2018
- Last trade
- 26 Aug 2026
- Last filed
- 28 Aug 2026
Companies traded
Activity over time
Not enough dated trades to draw.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 26 Aug 2026filed 28 Aug 2026 | URGN UroGen PharmaBiotechnology | SEC FORM 4 Code M | —2,000 | filing |
| 26 Aug 2026filed 28 Aug 2026 | URGN UroGen Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,000 at $0.00 | filing |
| 26 Aug 2026filed 28 Aug 2026 | URGN UroGen Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,000 at $0.00 | filing |
| 26 Aug 2026filed 28 Aug 2026 | URGN UroGen PharmaBiotechnology | SEC FORM 4 Code M | —2,000 | filing |
| 22 Jun 2026filed 24 Jun 2026 | URGN UroGen Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 22 Jun 2026filed 24 Jun 2026 | URGN UroGen Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —8,000 at $0.00 | filing |
| 22 Jun 2026filed 24 Jun 2026 | URGN UroGen Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 22 Jun 2026filed 24 Jun 2026 | URGN UroGen Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —8,000 at $0.00 | filing |
| 26 May 2026filed 27 May 2026 | URGN UroGen PharmaBiotechnology | SEC FORM 4 Code M | —2,000 | filing |
| 26 May 2026filed 27 May 2026 | URGN UroGen Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,000 at $0.00 | filing |
| 26 May 2026filed 27 May 2026 | URGN UroGen Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,000 at $0.00 | filing |
| 26 May 2026filed 27 May 2026 | URGN UroGen PharmaBiotechnology | SEC FORM 4 Code M | —2,000 | filing |
| 10 Jan 2026filed 16 Jan 2026 | ELDN Eledon PharmaceuticalsBiotechnology | SEC FORM 4 Code M | —3,430 at $0.00 | filing |
| 10 Jan 2026filed 16 Jan 2026 | ELDN Eledon Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —3,430 at $0.00 | filing |
| 10 Jan 2026filed 16 Jan 2026 | ELDN Eledon Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —3,430 at $0.00 | filing |
| 10 Jan 2026filed 16 Jan 2026 | ELDN Eledon PharmaceuticalsBiotechnology | SEC FORM 4 Code M | —3,430 at $0.00 | filing |
| 26 Nov 2025filed 1 Dec 2025 | URGN UroGen Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,000 at $0.00 | filing |
| 26 Nov 2025filed 1 Dec 2025 | URGN UroGen PharmaBiotechnology | SEC FORM 4 Code M | —2,000 | filing |
| 26 Aug 2025filed 27 Aug 2025 | URGN UroGen Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 26 Aug 2025filed 27 Aug 2025 | URGN UroGen Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —8,000 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.
Sectors
No trade we could place in a sector.